Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAEL-101 plus plasma cell dyscrasia treatment versus placebo plus plasma cell dyscrasia treatment in treatment-naive Mayo stage IIIb AL amyloidosis
NL-OMON51561Phase 3Withdrawn
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in light-chain amyloidosis comparing CAEL-101 + plasma cell dyscrasia treatment with Placebo + plasma cell dyscrasia treatment (2 arms). Primary endpoints: Time to all-cause mortality and Safety and tolerability. Planned start Mar 2022; status: withdrawn.
02
Drugs
anselamimab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NL-OMON51561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51561.